Related Experiment Videos
Reactive stroma in prostate cancer progression
J A Tuxhorn1, G E Ayala, D R Rowley
1Department of Molecular and Cellular Biology and Pathology, Baylor College of Medicine, Houston, Texas, USA.
The Journal of Urology
|November 7, 2001
Summary
Reactive stroma in cancer mirrors wound healing, promoting tumor growth. Understanding these processes, particularly transforming growth factor-beta in prostate cancer, offers new diagnostic and therapeutic avenues.
Area of Science:
- Oncology
- Cancer Biology
- Tumor Microenvironment
Background:
- The tumor microenvironment, specifically reactive stroma, is altered in many cancers.
- Reactive stroma plays a crucial role in cancer progression and is regulated by carcinoma.
Purpose of the Study:
- To review the literature on reactive stroma characteristics, its effect on cancer progression, and its regulation by carcinoma.
- To propose a hypothesis for reactive stroma in prostate cancer.
- To explore potential diagnostic and therapeutic applications of reactive stroma biology.
Main Methods:
- Extensive literature search on wound repair stroma, general stromal responses to carcinoma, and prostate cancer stromal biology.
- Analysis of reviewed studies to develop a reactive stroma hypothesis in prostate cancer.
Main Results:
- Tumor stroma modifications in breast, colon, and prostate cancers resemble granulation tissue in wound repair.
- Key changes include stromal cell phenotypic switching, extracellular matrix remodeling, and angiogenesis induction.
- Transforming growth factor-beta is identified as a potential regulator of reactive stroma due to its role in wound repair and overexpression in prostate cancer.
Conclusions:
- Reactive stroma in prostate cancer and wound repair exhibit similar biological processes that likely promote cancer progression.
- Further research into specific functional and regulatory mechanisms of reactive stroma in prostate cancer is needed.
- Identifying these mechanisms may lead to novel diagnostic and therapeutic strategies for prostate cancer.